Compare Marqeta Inc (MQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Repligen Corporation Common Stock — how do they compare? Marqeta Inc trades at $18.39 (market cap $1.89B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 6× Marqeta Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Repligen Corporation Common Stock for 0 Days on average.
| MQ | RGEN | |
|---|---|---|
Market Cap | $1.89B | $11.31B |
Volume | 809,068 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $20.32 | $194.57 |
52-Week Low | $15.04 | $102.87 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.21B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.56, up 1.48% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported three consecutive quarterly EPS beats, with Q3 2026 results expected soon. Revenue has recovered from $507M in 2024 to $625M in 2025, though net income remains negative. Positive cash flow trends emerged in 2025, with net cash flow turning positive at $86M.
The outlook is mixed: strong operational momentum and partnerships (e.g., with Google and BVNK) support growth, but high valuation ratios (P/E 206.22) and thin net margins (1.53%) pose risks. Analyst consensus is cautious with a $11.38 price target, implying downside, yet institutional sentiment is divided amid earnings improvements.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
